A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome

NCT02334306 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Sjögren's Syndrome

Interventions

BIOLOGICAL: AMG 557/MEDI5872
OTHER: Placebo

Sponsor

MedImmune LLC

Collaborators

[object Object]